Imara’s Sickle Cell Disease Therapy Impresses in Phase 2 Trial
On January 6th, Boston-based biotech, Imara Inc. announced promising Phase2a trial results of its Sickle Cell Disease Drug, IMR-687. When compared to the placebo, IMR-687 was well tolerated as a …
Read More